Beam Therapeutics (BEAM) closed at $24.03 on November 12, 2026, down 6.9% from the previous close, on volume of 1,389,723 shares (30-day average 1,809,455).
Data as of November 12, 2026.
12-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity
TipRanks (Wed, 11-Nov 8:36 AM ET)
TipRanks (Wed, 11-Nov 5:40 AM ET)
Analysts’ Top Healthcare Picks: Tecan Group AG (TCHBF), Beam Therapeutics (BEAM)
TipRanks (Tue, 10-Nov 2:50 PM ET)
Beam drops despite Phase 1/2 trial win for cell therapy in sickle cell disease
Seeking Alpha News (Tue, 10-Nov 11:55 AM ET)
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Globe Newswire (Wed, 4-Nov 9:00 AM ET)
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Tue, 27-Oct 7:00 AM ET)
PRNewswire (Thu, 15-Oct 10:02 AM ET)
Globe Newswire (Tue, 13-Oct 7:00 AM ET)
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Beam Therapeutics trades on the NASDAQ stock market under the symbol BEAM.
As of November 12, 2026, BEAM stock price declined to $24.03 with 1,389,723 million shares trading.
BEAM has a beta of 2.57, meaning it tends to be more sensitive to market movements. BEAM has a correlation of 0.25 to the broad based SPY ETF.
BEAM has a market cap of $2.47 billion. This is considered a Mid Cap stock.
Last quarter Beam Therapeutics reported $307,000 in Revenue and -$1.28 earnings per share. This fell short of revenue expectation by $-10 million and missed earnings estimates by -$.11.
In the last 3 years, BEAM traded as high as $49.50 and as low as $13.53.
The top ETF exchange traded funds that BEAM belongs to (by Net Assets): ARKE, ARKK, XBI, ARKG, VTI.
BEAM has underperformed the market in the last year with a price return of +6.9% while the SPY ETF gained +12.0%. BEAM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.5% and -16.5%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
BEAM support price is $24.72 and resistance is $26.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BEAM shares will trade within this expected range on the day.
